论文部分内容阅读
美国旧金山消息:使用组织纤维蛋白溶酶原激活剂(tPA)早期治疗卒中的临床研究可能于今年夏季末开始。应用tPA已成功地阻止了进行性心脏病发作。tPA的动物研究(及另种血块溶解蛋白尿激酶的研究)表明此药能在人为的卒中试验中保护受试动物的神经功能。 Justin Zivin试用tPA治疗家兔血栓。在对12只家兔颈动脉内注射血凝块后2分
SAN FRANCISCO, USA: Clinical study of early treatment of stroke with tissue plasminogen activator (tPA) may start later this summer. The use of tPA has succeeded in preventing a heart attack. Animal studies of tPA (and studies of another clot-dissolving protein urokinase) have shown that the drug protects the neurological function of test animals in an artificial stroke trial. Justin Zivin Trial tPA Treatment of Rabbit Thrombosis. Two rabbits were injected with clot in the carotid artery of 12 rabbits